Erratum: Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth (Human Molecular Genetics (2015) 24: 17 (4775–4779) DOI: 10.1093/hmg/ddv182);Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth

Human Molecular Genetics

Volumn 24, Issue 17, 2015, Pages 4775-4779

  Loveday, Chey ^a   Tatton Brown, Katrina ^a,b,c   Clarke, Matthew ^a   Westwood, Isaac ^a   Renwick, Anthony ^a   Ramsay, Emma ^a   Nemeth, Andrea ^d   Campbell, Jennifer ^e   Joss, Shelagh ^f,g   Gardner, McKinlay ^h   Zachariou, Anna ^a   Elliott, Anna ^a   Ruark, Elise ^a   van Montfort, Rob ^a   Rahman, Nazneen ^a,c   The Childhood Overgrowth Collaboration, ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f Southern General Hospital   (United Kingdom)

^g CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^h WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 5B; PHOSPHOPROTEIN PHOSPHATASE 5C; PHOSPHOPROTEIN PHOSPHATASE 5D; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PPP2R5B PROTEIN, HUMAN; PPP2R5C PROTEIN, HUMAN; PPP2R5D PROTEIN, HUMAN;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; BODY HEIGHT; CHILD; CRYSTAL STRUCTURE; EXOME; GENE MUTATION; GROWTH DISORDER; HEAD CIRCUMFERENCE; HETEROZYGOTE; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; OVERGROWTH SYNDROME; PHENOTYPE; PRIORITY JOURNAL; CHEMISTRY; GENETIC ASSOCIATION STUDY; GENETICS; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION;

EXOME; GENETIC ASSOCIATION STUDIES; GROWTH DISORDERS; HUMANS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MUTATION; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN PHOSPHATASE 2;

EID: 84940596143     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/HMG/DDY424     Document Type: Erratum

References (14)

1. Tatton-Brown, K. andWeksberg, R. (2013) Molecular mechanisms of childhood overgrowth. Am. J. Med. Genet. C Semin. Med. Genet., 163c, 71-75.
2. Tatton-Brown, K., Hanks, S., Ruark, E., Zachariou, A., Duarte Sdel, V., Ramsay, E., Snape, K., Murray, A., Perdeaux, E.R., Seal, S. et al. (2011) Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget, 2, 1127-1133.
3. Tatton-Brown, K., Seal, S., Ruark, E., Harmer, J., Ramsay, E., del Vecchio Duarte, S., Zachariou, A., Hanks, S., O'Brien, E., Aksglaede, L. et al. (2014) Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat. Genet., 46, 385-388.
4. Seshacharyulu, P., Pandey, P., Datta, K. and Batra, S.K. (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett., 335, 9-18.
5. Saraf, A., Oberg, E.A. and Strack, S. (2010) Molecular determinants for PP2A substrate specificity: charged residues mediate dephosphorylation of tyrosine hydroxylase by the PP2A/ B' regulatory subunit. Biochemistry, 49, 986-995.
6. The Deciphering Developmental Disorders Study. (2014) Large-scale discovery of novel genetic causes of developmental disorders. Nature, 519, 223-228.
7. Rocher, G., Letourneux, C., Lenormand, P. and Porteu, F. (2007) Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J. Biol. Chem., 282, 5468-5477.
8. Rodgers, J.T., Vogel, R.O. and Puigserver, P. (2011) Clk2 and B56beta mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol. Cell, 41, 471-479.
9. Mester, J. and Eng, C. (2013) When overgrowth bumps into cancer: the PTEN-opathies. Am J Med. Genet. C Semin. Med. Genet., 163c, 114-121.
10. Mirzaa, G.M., Riviere, J.B. and Dobyns,W.B. (2013) Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. Am. J. Med. Genet. C Semin. Med. Genet., 163c, 122-130.
11. Lindhurst, M.J., Sapp, J.C., Teer, J.K., Johnston, J.J., Finn, E.M., Peters, K., Turner, J., Cannons, J.L., Bick, D., Blakemore, L. et al. (2011) A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med., 365, 611-619.
12. Samocha, K.E., Robinson, E.B., Sanders, S.J., Stevens, C., Sabo, A., McGrath, L.M., Kosmicki, J.A., Rehnstrom, K., Mallick, S., Kirby, A. et al. (2014) A framework for the interpretation of de novo mutation in human disease. Nat. Genet., 46, 944-950.
13. Xu, Z., Cetin, B., Anger, M., Cho, U.S., Helmhart,W., Nasmyth, K. and Xu, W. (2009) Structure and function of the PP2Ashugoshin interaction. Mol. Cell., 35, 426-441.
14. McNicholas, S., Potterton, E., Wilson, K.S. and Noble, M.E.M. (2011) Presenting your structures: the CCP4 mg molecular-graphics software. Acta Crystallogr. D, 67, 386-394.